Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Problems with Generics Pointed Out in 19/40 Studies
October 15, 2007
- Merck Serono Sets Out Focusing on Cancer, Infertility
October 15, 2007
- 3 Domestic Generic Firms to Hold IR Meeting in London
October 15, 2007
- Mylan Enters Market in Japan by Acquiring Merck's Generic Drug Business
October 15, 2007
- Public Opinions Invited on Documents Required for Applications for Generics
October 15, 2007
- Mitsubishi Tanabe Pharma Corp. Aims at Becoming Global Drug Discovery Company
October 15, 2007
- Kaken Completes PIIb Trial for KCB-1D as Drug to Regenerate Periodontal Tissue
October 15, 2007
- Taisho Licenses Psychiatric Drug Candidates to BrainCells
October 15, 2007
- Silodosin Was Found to Be Superior to Tamsulosin: Kissei
October 15, 2007
- EPS Ties Up with Medidata Solutions Regarding EDC Software
October 15, 2007
- First Gene Therapeutic to Regenerate Blood Vessels Expected in 2008
October 15, 2007
- VITAL-NET, KSK Enter into Comprehensive Business Alliance
October 15, 2007
- Physician-Initiated Trials Led by JMACCT Generating Results
October 15, 2007
- Council Recommends Improvements of Drug Trade Practices
October 15, 2007
- Guideline Issued on Multinational Cooperative Clinical Studies
October 15, 2007
- BUSINESS NEWS IN BRIEF
October 15, 2007
- Number of Documents Necessary for Clinical Trials Halved
October 15, 2007
- TOPICS／2007 JCA-Mauvernay Award Granted to 2 Japanese Scientists
October 15, 2007
- Korosho Proposes Higher Premiums for Pediatric and Orphan Drugs: Chuikyo
October 15, 2007
- R&D NEWS IN BRIEF
October 15, 2007
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…